Merck (NYSE:MRK) posted net income of $1.6 billion in the third quarter, eclipsing its performance for the same time last year, aided by its cervical cancer vaccine and strong growth in China.
Revenue for the Whitehouse Station, New Jersey pharmaceutical company for the quarter rose 8 percent to $12 billion. Sales of combination diabetes drug Janumet and cervical cancer vaccine Gardisal helped bolster prescription drug sales, helped by demand in Japan, the newest market for the vaccine. Sales of the vaccine were also helped by an increasing number of boys being vaccinated, the company said in the conference call.
It, too, has a blockbuster drug with an exclusive patent end date that is approaching with its asthma drug, Singulair, which had third-quarter sales of $1.3 billion, a 10 percent increase.
Behavioral Health, Interoperability and eConsent: Meeting the Demands of CMS Final Rule Compliance
In a webinar on April 16 at 1pm ET, Aneesh Chopra will moderate a discussion with executives from DocuSign, Velatura, and behavioral health providers on eConsent, health information exchange and compliance with the CMS Final Rule on interoperability.
Merck has seen a 50 percent increase in sales in China compared with the previous year and anticipates a 30 percent increase in sales in China for the year for patented and unpatented products, Adam Schecter, the president of global human health, said in the conference call. He added that it would discuss the growth in more detail at a business briefing set for Nov. 10.
Last month, Merck formed a strategic collaboration with Beijing-based BGI, one of the the world’s largest genomics centers, to focus on the discovery and development of biomarkers and genomics technologies.
Merck is still digesting its $41 billion acquisition of Schering-Plough from 2009. And job cuts announced earlier this year are continuing to take effect.